SOPHiA GENETICS to Report Second Quarter 2021 Financial Results on September 9, 2021
SOPHiA GENETICS (Nasdaq: SOPH) announced that it will release its financial results for Q2 2021 on September 9, 2021, before market opening. A conference call will follow at 8:30 a.m. ET to discuss these results, business developments, and future outlook. The company emphasizes its commitment to data-driven medicine through its SOPHiA DDM™ Platform, utilized by over 780 healthcare institutions globally, reinforcing its strategic position in the healthcare technology landscape.
- SOPHiA DDM™ Platform used by over 780 institutions.
- Focus on establishing data-driven medicine as standard care.
- None.
Insights
Analyzing...
BOSTON and LAUSANNE, Switzerland, Aug. 26, 2021 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH) today announced it will report financial results for the second quarter of 2021 before market open on Thursday, September 9, 2021. The company’s management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time to discuss its results, business developments, and outlook.
Live audio of the webcast will be available on the “Investors” section of the company website at: ir.sophiagenetics.com. An archived replay will be available on the company’s website following the event.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by more than 780 hospital, laboratory, and biopharma institutions globally.
Media Contact:
sophiagenetics@consortpartners.com
Investor Contact:
ir@sophiagenetics.com
Carrie Mendivil
carrie@gilmartinir.com
